These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 21974700

  • 21. Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β2-microglobulin-related amyloidosis and indoxyl sulfate-induced atherosclerosis-Oshima Award Address 2016.
    Yamamoto S.
    Clin Exp Nephrol; 2019 Feb; 23(2):151-157. PubMed ID: 29869756
    [Abstract] [Full Text] [Related]

  • 22. Historical background and clinical treatment of dialysis-related amyloidosis.
    Yamamoto S, Gejyo F.
    Biochim Biophys Acta; 2005 Nov 10; 1753(1):4-10. PubMed ID: 16226497
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Diagnosis and therapy for beta2-microglobulin amyloidosis in the K/DOQI guideline].
    Higuchi N, Maruyama H.
    Clin Calcium; 2004 May 10; 14(5):744-9. PubMed ID: 15577036
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Amyloidosis associated with long-term dialysis].
    Gejyo F, Maruyama H, Arakawa M.
    Nihon Jinzo Gakkai Shi; 1995 Jan 10; 37(1):1-6. PubMed ID: 7699947
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Serum beta 2-microglobulin concentration and its removal in patients treated with continuous ambulatory peritoneal dialysis].
    Kubo H, Kawaguchi Y, Aizawa S, Morita T, Nakayama M, Wakabayashi Y, Watanabe S, Ogawa A, Sakai O.
    Nihon Jinzo Gakkai Shi; 1990 Apr 10; 32(4):419-26. PubMed ID: 2198365
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients.
    Schiffl H.
    Hemodial Int; 2014 Jan 10; 18(1):136-41. PubMed ID: 23718290
    [Abstract] [Full Text] [Related]

  • 36. Direct hemoperfusion with a beta2-microglobulin-selective adsorbent column eliminates inflammatory cytokines and improves pulmonary oxygenation.
    Kono K, Toda S, Hora K, Kiyosawa K.
    Ther Apher Dial; 2009 Feb 10; 13(1):27-33. PubMed ID: 19379167
    [Abstract] [Full Text] [Related]

  • 37. [Cystatin C, beta2-microglobulin and C-reactive protein in hemodiafiltration and on-line endogenous liquid reinfusion and in low flux polysulphone bicarbonate conventional hemodialysis].
    Cristofano C, Vernaglione L, Perniola MA, Lo Barco C, Muscogiuri P, Chimienti S.
    G Ital Nefrol; 2004 Feb 10; 21 Suppl 30():S197-200. PubMed ID: 15750984
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Significance of serum levels of beta-2-microglobulin in dialysis patients].
    Baldrati L, Baldrati L, Delvecchio C, Capponcini C, Docci D, Turci F, Feletti C.
    Recenti Prog Med; 1990 Sep 10; 81(9):561-3. PubMed ID: 2263750
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.